Drugs / Ropidoxuridine
Ropidoxuridine
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT04406857 | Mar 2021 → Jan 2023 | rectum adenocarcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02993146 | May 2017 → Aug 2022 overdue | hematopoietic and lymphoid cell neoplasm, metastatic malignant neoplasm in the brain | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02381561 | Feb 2016 → Nov 2018 overdue | bile duct carcinoma, esophageal cancer, gastric carcinoma, rectal carcinoma +1 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01240577 | Oct 2010 → Jul 2012 | lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06359379 | Sep 2024 → Dec 2025 | IDH-wildtype glioblastoma | Shuttle Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ropidoxuridine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06359379 ↗ |
| Known as | IPdR | “determine the recommended phase -2 dose of ropidoxuridine (5-iodo-2-pyrimidinone-2'-deoxyribose \[IPdR\]) when administered alone orally once daily for 7 consecutive days” NCT02993146 ↗ |
| Known as | NSC 726188 | “IPdR (NSC 726188) is an orally administered prodrug of IdUrd with a better therapeutic index in preclinical models.” NCT01240577 ↗ |
| Known as | Ropidoxuridina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103821 ↗ |
| Modality | Small molecule | — CHEMBL2103821 ↗ |
| Route | Oral | “single oral dose of IPdR” NCT01240577 ↗ |